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hospitalization from heart failure, and cerebrovascular events. Logistic regression of 
potential-confounders at PD initiation was performed to determine propensity scores 
(PS), probability of prescribing colchicine. PS and covariates were controlled in multi-
variable Cox hazard regression models to investigate association of colchicine and CV 
events. Results: Of 366 subjects, 57 (15.6%) received colchicine, 75 (20.5%) had history 
of CV events. Follow-up was shorter in the non-users, 19.1 months median (range 
3.05-70.0) vs. 26.5 (3.2-71.3). CV events occurred in 7 (12.3%) in the users and 82 (26.5%) 
in the non-users. Both groups did not differ on entry Charlson co-morbidity index, 
estimated glomerular filtration rate, serum uric acid levels. Adjusted hazard ratio (HR) 
of CV events was lower in colchicine users for primary CV events (adjHR 0.28; 95% CI, 
0.09-0.90, p= 0.033), and secondary CV events (adjHR 0.29; 95% CI, 0.08-0.99, p= 0.049). 
Moreover, colchicine users had fewer CV mortality and all-causes mortality, although 
statistical significance was not found. ConClusions: Colchicine appeared to associ-
ate with reducing risk of primary and secondary CV events, and demonstrated trends 
toward lower CV mortality and all-causes mortality in PD patients.
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objeCtives: To investigate the management of hypertension in adult Malaysian 
population suffering from chronic kidney disease stage (CKD) stage 3-5. Methods: 
A retrospective, cross-sectional study was conducted on 300 patients with CKD stage 
3 (n = 98), 4 (n = 76) and 5 (n = 126) in CKD Resource Center of Hospital University 
Science Malaysia, Kelantan, Malaysia. Results: The mean age of all patients was 
58.86 ± 13.47 years and there was preponderance of male subjects (69%). The preva-
lence of hypertension was 91.3%; almost universal among the sufferers of stage 3, 
4 and 5 of CKD (87.8%, 94.7% and 92.1%, respectively). In CKD stage 5, mean systolic 
blood pressure was considerably higher than in stage 4 and 3 (p = 0.009).The per-
centage of patients with systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg was 
30.3% and 49.0%, respectively. Only 24.3% of the total patients had BP < 130/80 mm 
Hg despite usingmultiple antihypertensive medications. The proportion of patients 
consuming antihypertensive drugs was as: angiotensin-converting enzyme inhibi-
tors (ACE-Is) (25%), angiotensin receptor blockers (ARBs) (14.3%),combined ACE-Is and 
ARBs (2.7%), calcium channel blockers (66.3%), β -blockers (40.7%), diuretics (60%) and 
α -blockers (14.3%). There was significantly lower percentage of patients on ACE-Is 
and ARBs in stage 5 than in stage 4 and 3 CKD patients. Proteinuria was present in 
71.7% of the patients and there was significant difference proteinuria between stage 
3, 4 and 5 (55.1 vs 59.2 vs 92.1, p = 0.000). ConClusions: Underutilization of some 
classes of anti-hypertensive medications is apparent.Higher percentage of proteinuria 
in CKD stage 5 patients may be attributed to the underuse of ACE-Is and ARBs in stage 
5.The study further indicated the need of employinginstructive efforts to get valuable 
outcomes of antihypertensive treatment in CKD sufferers.
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objeCtives: The beneficial effects of implantable cardioverter defibrillators (ICDs) 
in primary and secondary prevention patients are well established. However, data on 
potential differences between both groups in mortality and ICD therapy rates during 
long-term follow-up are scarce. The aim of the study was to assess differences in 
mortality and ICD therapy between secondary and primary prevention ICD recipi-
ents. Methods: All patients treated with an ICD, regardless of the underlying cardiac 
pathology, at the island of Crete were included in the current analysis. The study 
population was grouped by the type of prevention (secondary or primary) for sudden 
cardiac death. The primary endpoint was all-cause mortality. The secondary endpoint 
was the occurrence of device therapy (appropriate or inappropriate). Results: A 
total of 854 (88.6% men) ICD recipients were included. Of these, 623 (73%) patients 
received an ICD for primary prevention of sudden cardiac death and 231 (27%) patients 
for secondary prevention. During a mean follow-up of 12,4 +/-7,8 years, 177 (20.7%) 
patients died. The incidence of mortality was 35,5% for secondary prevention patients 
and 15.2% for primary prevention patients (p< 0.001). Ventricular arrhythmia triggered 
appropriate therapy in 91 (39,4%) secondary prevention patients. Accordingly the 
number of primary prevention patients that received appropriate therapy was 126 
(20,2%). A comparable risk for inappropriate shocks was observed. ConClusions: 
During long-term follow-up, primary prevention patients exhibited a lower risk all-
cause mortality. Both groups showed similar occurrence of inappropriate shocks but 
secondary prevention patients showed a higher rate of appropriate therapy.
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objeCtives: Catheter-based renal denervation (RDN) is a promising therapy option 
for patients with treatment resistant hypertension (TR-HTN). The RDN evidence base 
currently consists of several studies with limited sample size and variations in design, 
on subjective and objective methods of patients’ assessment. Assessment made by 
nurses with bachelor degree is different from assessment made by ordinary nurses 
(P< 0.05). 2. Assessment made by asking questions, physical examination of patients 
with arterial hypertension mostly defined symptoms of functional dysfunction of 
cardiovascular system like dyspnoea, edema, chest pain, peripheral cyanosis, hyper-
trophy left ventricular, and these symptoms can be theoretical and methodological 
aspects of nursing diagnosis. 3. Symptoms, first and secondary risk factors of arte-
rial hypertension defined by laboratory investigations, asking questions, physical 
examination (increased level of blood sugar, cholesterol, triglycerides, decreased level 
of LDLP, increased systolic and diastolic blood pressure). These findings can be theo-
retical and methodological aspects for nursing diagnosis.
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objeCtives: To evaluate the relative effectiveness of cardiac resynchronization 
therapy (CRT) versus implantable cardiac defibrillator (ICD) or optimal medical treat-
ment (OMT) in mild-moderate heart failure patients with New York Heart Association 
(NYHA) Class I and II. Methods: Randomized controlled trials of CRT, ICD and OMT 
in mild-moderate heart failure patients were identified from MEDLINE, EMBASE and 
COCHRANE database. All abstracts were identified for the search terms ‘mild-moder-
ate heart failure’, ‘CRT’, ‘ICD’, ‘OMT’ and ‘NYHA class I or II’. Abstracts were reviewed, 
and studies containing information on effectiveness profile were obtained for further 
review. Results were pooled and analyzed by a Bayesian random-effect model. The 
model used to analyze the relative effectiveness of all-cause mortality and left ventric-
ular ejection fraction (LVEF). Results: 11 studies were identified with a total of 6,865 
patients. CRT was associated with a significant reduction of the all-cause mortality 
compared with ICD alone (odds ratio 0.81, 95% credible interval 0.60 to 1.14) or OMT 
alone (odds ratio 0.59, 95% CrI 0.39 to 0.95). CRT also had a substantial improvement 
of LVEF compared with ICD treatment (mean difference 3.96, 95% CrI 0.88 to 7.08). The 
probability determined from the Bayesian analysis that CRT was the best treatment 
option was 87.2% (7.7% for ICD and 0.9% for OMT respectively). ConClusions: This 
Bayesian network meta-analysis suggests that CRT could improve the prognosis in 
patients with mild-moderate heart failure.
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objeCtives: The safety of statins had been a controversial issue. Cerivastatin was 
withdrawn due to fatal rhabdomylosis, and the high dose of simvastatin was reported 
to cause liver failure. This study aims to compare the preferences on the benefits and 
risks of statins between the patients and physicians. Methods: Discrete choice 
experiments (DCE) were conducted to measure preferences on the benefits and risks 
of statins. Two benefit parameters were defined as low-density lipoprotein cholesterol 
reduction (LDL) and myocardial infraction reduction (MI). And two risk attributes 
contained liver failure (Liv) and fatal rhabdomylosis (Rha). The questionnaires for 
the DCE were designed to satisfy orthogonality, level balance and minimum overlap. 
287 subjects (patients 205, physician 82) were participated and repeatedly evaluated 
a choice set including two hypothetical statins with different level of each attributes. 
The survey was performed by face-to-face method among Korean patients who take 
anti-hypertensive or cholesterol-lowering drug, and hospital physicians who treat 
cardiovascular disease. The data were analyzed by conditional logit (SAS 9.3 soft-
ware). Results: The physicians elicited the preferences for LDL [Mean(±SD):40.14% 
(±0.06)], MI 30.09%(±0.21), Liv 20.16%(±0.45) and Rha 9.55%(±0.29). While the patients 
estimated 38.88%(±0.15), 36.32%(±0.33), 11.55% (±0.35), 13.25%(±0.14) respectively. 
Regarding the willingness to accept risk in exchange for benefit of statins, the physi-
cians accepted risk twice than patients when the statin reduced the MI from 25% to 
40% but caused the average hepatotoxicity from 1% to 5%. ConClusions: Preference 
for the benefits of statins outweighs those of the risks in all respondents. However 
physicians consider greater importance of the Liv than the Rha while patients are 
opposite. Physicians and patients need try to narrow the perception gap regarding 
the risk of statins before starting treatment. Acknowledge This was supported by the 
grant (13182MFDS703) form Mistry of Food and Drug Safety.
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objeCtives: In peritoneal dialysis (PD) patients, remarkably high risk of cardiovascu-
lar (CV) mortality may be explained by atherosclerosis and inflammation. Colchicine 
has been illustrated to suppress inflammatory mediators via prevention of choles-
terol crystal-induced neutrophil, and reduces atherosclerosis progression. This study 
aimed to explore benefit of colchicine use on primary and secondary CV events, CV 
mortality, and all-causes mortality in PD patients. Methods: Subjects were first-
ever PD patients for ≥ 3 months, and ≥ 18 years old from January 2007 to October 
2013 in a retrospective cohort of the PD registry of Nakornping Hospital, Chiang Mai, 
Thailand. Users of colchicine for ≥ 3 months were compared to non-users. CV events 
were the composite incidence of acute myocardial infarction or unstable angina, 
